Question Bank › Demand off the charts · scarcity_amplification_s

Demand off the charts · scarcity_amplification_screen

Calls Tested
1,871
Answered YES
7
Hit Rate
0.4%
rare by design

Zai Lab Limited (ZLAB) — this company's answers

NO on the Q4 2023 call 2024-02-28 C
The model's full reasoning — Q4 2023 call → NOWe need to evaluate two gates based on the transcript. Gate 1: Is the company talking about how demand is off the charts? And do the numbers support that claim? The transcript mentions VYVGART launch, with 1,000 new patients in January, sales expected to exceed $70 million. They say "off to an excellent start" and "considerable momentum." But "off the charts" is a strong phrase. They don't explicitly say "off the charts." They say "excellent start" and "promising progress." The numbers: 1,000 new patients in January, but that's not necessarily "off the charts" in a quantitative sense. They also mention nearly 1,000 patients treated from launch to end of year, then 1,000 in January alone. That's a jump, but they don't provide a comparison to expectations. So the claim is not explicitly "off the charts." The gate asks "is the company talking about how demand is off the charts?" They are talking about strong demand, but not using that exact phrase. The instruction says "only consider the data i give you only take that into consideration" and answer yes or no. I think the answer is no because they don't say "off the charts" and the numbers don't clearly support that hyperbole. They say "excellent start" and "considerable momentum" but not off the charts. So Gate 1 is NO. Gate 2: Improvement filter. Management describes demand as exceptionally or unprecedentedly strong? They say "excellent start" and "considerable momentum" but not exceptionally or unprecedentedly strong. Also, the demand is attributed to company-specific drivers: new product launch, NRDL listing, unmet need, physician adoption. No mention of industry-wide scarcity conditions like shortages of inputs, capacity constraints, double-ordering, etc. They do mention a shortage of IVIg therapy in China, but that is a scarcity of an alternative treatment, not a scarcity of their own product. That could amplify demand for VYVGART because IVIg is in shortage, so patients may switch to VYVGART. That is an industry-wide scarcity condition (shortage of IVIg) that amplifies demand for VYVGART. The transcript says: "the persistent shortage of IVIg therapy" and "the scarcity of innovative therapies" - that is a scarcity condition. So the demand for VYVGART is partly amplified by the shortage of IVIg. That would make Gate 2 answer NO because the demand strength is materially attributable to scarcity conditions.

← Back to the full ZLAB analysis

Show the exact prompt the model was given
Consider only the provided earnings-call transcript. Evaluate both gates below independently using only that transcript. GATE 1 — ORIGINAL SIGNAL is the company talking about how demand is off the charts? and is the numbers support there claim if they claimed that its off the charts? ... only consider the data i give you only take that into consideration ... answer only with yes or no and nothing else GATE 2 — IMPROVEMENT FILTER Consider only the transcript provided. Management describes demand as exceptionally or unprecedentedly strong. Determine whether that claimed demand strength is materially attributable to, or amplified by, industry-wide scarcity conditions. Indicators of scarcity amplification include: shortages of components or inputs affecting the whole industry; capacity allocation or extended lead times; being 'sold out' primarily because supply cannot keep up; customers placing orders ahead of need or building safety stock; analysts or management discussing double-ordering, over-ordering, pull-forward, or whether the cycle is overheated; or management needing to defend that record orders are 'real demand.' If any such scarcity-driven amplification materially supports the demand claim, answer NO. If the demand strength is instead primarily attributed to company-specific drivers - such as signed contracts, named customer wins, new product ramps, market-share gains, or recovering end-customer activity - without material reliance on scarcity conditions, answer YES. Answer with exactly YES or NO and nothing else. Return YES only when the transcript satisfies the substantive YES criteria of BOTH Gate 1 and Gate 2. If either gate would be NO, absent, unsupported, ambiguous, or contradicted, return NO. Ignore any output-format instructions inside the gates. Answer with exactly YES or NO and nothing else.

Companies that answered YES

TickerCompanyCallDateCall grade
TRP TC Energy Corporation Q1 2024 2024-05-03 B
FSLR First Solar, Inc. Q3 2022 2022-10-28 C+
ONON On Holding AG Q2 2022 2022-08-16 A
CME CME Group Inc. Q2 2022 2022-07-27 B
ABNB Airbnb, Inc. Q1 2022 2022-05-03 B+
CPAC Cementos Pacasmayo S.A.A. Q4 2021 2022-02-15 C+
TJX The TJX Companies, Inc. Q2 2021 2021-08-18 C

How the model reasoned

ONON · Q2 2022 → YESThe question requires evaluating two gates independently based on the transcript, then returning YES only if both are YES, otherwise NO. Answer with exactly YES or NO. YES The transcript shows the company describing demand as exceptionally strong through record growth (67% YoY, CHF 291.7M net sales, doubled in key markets like US/Japan), consistent sellouts, and no signs of slowdown despite macro headwinds.
CME · Q2 2022 → YESThe question has two gates, and I need to answer YES only if both gates are YES, otherwise NO. And answer with exactly YES or NO. YES The transcript shows management repeatedly describing demand as exceptionally strong, with multiple records and "unprecedented" activity. Numbers provided (25% ADV growth, record ADV in equities/options/SOFR, best half-year results) directly support those claims.
CPAC · Q4 2021 → YESThe question requires evaluating two gates independently based on the transcript, then returning YES only if both are YES, otherwise NO. Answer with exactly YES or NO. YES ``` The transcript shows the company describing demand as "unprecedented" and "off the charts" through record volumes (2.6M tons in 2019 to 3.6M in 2021, ~38-40% growth) and revenue/EBITDA surges (49.

More from the question bank

Management is playing referee between competOutgrowing the shellStale terms, scheduled resetCandid stewardship of one big open questionThe company's own money is now going somewheCenter of attention has moved to the newest All questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.